28-Day Intranasal Toxicity Study Of MMS019 In Sprague Dawley Rats And Dogs

By Kyle Klepner, Sheila Mathias, Jeffrey Gudin, and Ijeoma Uchegbu

MMS019 is an innovative, carbohydrate-based antiviral nasal prophylactic currently in development, designed to act as a nasal barrier or "masking spray" to prevent the transmission of viruses, including SARS-CoV-2. The product contains the active ingredient quaternary ammonium palmitoyl glycol chitosan (GCPQ), a self-assembling, mucoadhesive trimethylammonium chitosan polymer. This polymer forms nanoparticles that cluster into microparticles optimized for nasal delivery. Once administered, these GCPQ microparticles are anticipated to electrostatically bind to the spike proteins of the SARS-CoV-2 virus, effectively blocking the virus from entering host cells and reducing the potential for transmission. This novel approach leverages the unique properties of GCPQ to provide a simple, preventative solution to viral spread.